Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I intranasal Ampligen safety and mucosal immune response study in healthy volunteers
NL-OMON50834Phase 1Completed
- Sponsor
- AIM ImmunoTech
- Start
- Feb 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Intranasal Ampligen with Intranasal placebo (2 arms). Primary endpoints: Frequency of local treatment-emergent adverse events, Frequency of systemic treatment-emergent adverse events and 8 more. Started Feb 2021; status: completed.
02
Drugs
rintatolimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50834.